ConductScience.org, home

Paper28596308

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT and 45 others. Science, 2017. Cited by 5,477 papers, by iCite.

Cite this record

ConductScience Library. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Papers, record 28596308. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28596308

Download JSON
Disease
colorectal cancer741 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
PubMed
Journal
Science
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
5,477
iCite
Relative citation ratio, by iCite
186
iCite
Revised in PubMed
2023-02-23
PubMed

Authors46

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Le DTDung Thttps://orcid.org/0000-0002-2110-7697
2Durham JNJennifer Nhttps://orcid.org/0000-0001-9097-9125
3Smith KNKellie Nhttps://orcid.org/0000-0002-6295-8930
4Wang HHao
5Bartlett BRBjarne Rhttps://orcid.org/0000-0001-8579-0379
6Aulakh LKLaveet K
7Lu SStevehttps://orcid.org/0000-0002-8201-8583
8Kemberling HHollyhttps://orcid.org/0000-0002-2997-324X
9Wilt CCarahttps://orcid.org/0000-0002-4054-7452
10Luber BSBrandon S
11Wong FFayhttps://orcid.org/0000-0001-9759-3778
12Azad NSNilofer S
13Rucki AAAgnieszka A
14Laheru DDan
15Donehower RRoss
16Zaheer AAtifhttps://orcid.org/0000-0002-4824-6654
17Fisher GAGeorge A
18Crocenzi TSTodd Shttps://orcid.org/0000-0001-8762-1990
19Lee JJJames Jhttps://orcid.org/0000-0001-6749-9350
20Greten TFTim Fhttps://orcid.org/0000-0002-0806-2535

Source PubMed

See all 46 authorsDownload CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Biomarkers, TumorMajor topic
Brain NeoplasmsMajor topic
Colorectal NeoplasmsMajor topic
Neoplastic Syndromes, HereditaryMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
Cell Cycle Checkpoints
DNA Mismatch Repair
Disease-Free Survival
Female
Humans
Male
Middle Aged
Mutation
T-Lymphocytes
Young Adult

Source PubMed

Download CSV of topics

Grants17

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U01 CA067941NCI NIH HHSUnited StatesR01CA067941PubMed and NIHNIH RePORTER
T32 GM007309NIGMS NIH HHSUnited StatesT32GM007309PubMed and NIHNIH RePORTER
K12 CA090625NCI NIH HHSUnited StatesK12CA090625PubMedNIH RePORTER
Howard Hughes Medical InstituteUnited StatesPubMedPubMed
P50 CA098252NCI NIH HHSUnited StatesP50CA098252PubMed and NIHNIH RePORTER
R01 CA203891NCI NIH HHSUnited StatesR01CA203891PubMed and NIHNIH RePORTER
R37 CA057345NCI NIH HHSUnited StatesR01CA057345PubMed and NIHNIH RePORTER
P30 CA016058NCI NIH HHSUnited StatesP30CA016058PubMed and NIHNIH RePORTER
R01 CA057345NCI NIH HHSUnited StatesR01CA057345PubMed and NIHNIH RePORTER
K23 CA163672NCI NIH HHSUnited StatesK23CA163672PubMed and NIHNIH RePORTER
R01 CA067941NCI NIH HHSUnited StatesR01CA067941PubMed and NIHNIH RePORTER
R37 CA043460NCI NIH HHSUnited StatesR37CA043460PubMed and NIHNIH RePORTER
P50 CA062924NCI NIH HHSUnited StatesP50CA062924PubMed and NIHNIH RePORTER
P30 CA006973NCI NIH HHSUnited StatesP30CA006973PubMed and NIHNIH RePORTER
R37CA057345NIHNIH RePORTER
U01CA067941NIHNIH RePORTER
ZIABC011343NIHNIH RePORTER

Download CSV of grants

Trials19

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01876511Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)BackgroundClinicalTrials.gov
NCT03832621NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerBackgroundClinicalTrials.gov
NCT03895970Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsBackgroundClinicalTrials.gov
NCT04197219Pembrolizumab With Axitinib in Recurrent Endometrial CancerBackgroundClinicalTrials.gov
NCT04622423Advanced Therapies for Liver MetastasesBackgroundClinicalTrials.gov
NCT04866862Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal CancerResultsClinicalTrials.gov
NCT05097599StrataPATH™ (Precision Indications for Approved Therapies)BackgroundClinicalTrials.gov
NCT05119829Melanoma: Genomic Profiles, Molecular Markers and Therapeutic ImplicationsBackgroundClinicalTrials.gov
NCT05854030Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous CarcinomaResultsClinicalTrials.gov
NCT05933980Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal CancerBackgroundClinicalTrials.gov
NCT06004713Registry Study in MSI/dMMR Solid TumorsBackgroundClinicalTrials.gov
NCT06098560Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal PatientsBackgroundClinicalTrials.gov
NCT06370663First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAICResultsClinicalTrials.gov
NCT06709885HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon CancerResultsClinicalTrials.gov
NCT07550088BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesBackgroundClinicalTrials.gov
NCT07622667Correlation Analysis of Gene Characteristics of Malignant Tumors With PrognosisBackgroundClinicalTrials.gov
NCT07841236ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon CancerBackgroundClinicalTrials.gov
NCT07845565FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaBackgroundClinicalTrials.gov
NCT07854977Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in28619894In a major shift, cancer drugs go 'tissue-agnostic'.https://conductscience.org/library/papers/28619894PubMed
Comment in28751597Genetic biomarker for cancer immunotherapy.https://conductscience.org/library/papers/28751597PubMed
Comment in28811675Biomarkers: Matching mutations to immunotherapy response.https://conductscience.org/library/papers/28811675PubMed

Download CSV of comments and corrections

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125428504Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014https://conductscience.org/library/papers/25428504PubMed
225858804Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell2015https://conductscience.org/library/papers/25858804PubMed
323177514Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet2013https://conductscience.org/library/papers/23177514PubMed
410362805High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.Am J Pathol1999https://conductscience.org/library/papers/10362805PubMed
528031159Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.Cancer Discov2017https://conductscience.org/library/papers/28031159PubMed
625897158Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol2015https://conductscience.org/library/papers/25897158PubMed
725800770Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.J Clin Oncol2015https://conductscience.org/library/papers/25800770PubMed
825428505PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature2014https://conductscience.org/library/papers/25428505PubMed
927694933Classification and characterization of microsatellite instability across 18 cancer types.Nat Med2016https://conductscience.org/library/papers/27694933PubMed
1025765070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
118030745Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.Am J Pathol1994https://conductscience.org/library/papers/8030745PubMed
1225877891Personalized genomic analyses for cancer mutation discovery and interpretation.Sci Transl Med2015https://conductscience.org/library/papers/25877891PubMed
1316825502Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers.J Mol Diagn2006https://conductscience.org/library/papers/16825502PubMed
1419934295Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin Cancer Res2009https://conductscience.org/library/papers/19934295PubMed
1528129544Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Cell2017https://conductscience.org/library/papers/28129544PubMed
1625358689The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.Cancer Discov2015https://conductscience.org/library/papers/25358689PubMed
1715528789Development of a fluorescent multiplex assay for detection of MSI-High tumors.Dis Markers2004https://conductscience.org/library/papers/15528789PubMed
1818245491Epitope landscape in breast and colorectal cancer.Cancer Res2008https://conductscience.org/library/papers/18245491PubMed
199872311Genetic instabilities in human cancers.Nature1998https://conductscience.org/library/papers/9872311PubMed
2024157944Using synthetic templates to design an unbiased multiplex PCR assay.Nat Commun2013https://conductscience.org/library/papers/24157944PubMed

See all 32 referencesDownload CSV of references

Cited by4,039

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5,477 citations.

PMIDTitleJournalYearIn PapersSource
42984928Immunotherapy in Advanced Epithelial Ovarian Cancer: Successes and Frustrations.Oncol Res2026https://conductscience.org/library/papers/42984928PubMed
42983056A patient with Lynch syndrome and duodenal neuroendocrine carcinoma achieved a pathologic complete response to immune checkpoint inhibitor therapy selected based on comprehensive genomic profiling.Virchows Arch2026https://conductscience.org/library/papers/42983056PubMed
42973860Context-dependent cGAS-STING signaling in solid tumors: biological determinants, clinical implications, and biomarker-guided therapeutic strategies.Front Immunol2026https://conductscience.org/library/papers/42973860PubMed
42964829Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer.Front Immunol2026https://conductscience.org/library/papers/42964829PubMed
42953524Advances in immunotherapy for gastrointestinal malignancies.Front Immunol2026https://conductscience.org/library/papers/42953524PubMed
42945895Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective study.EBioMedicine2026https://conductscience.org/library/papers/42945895PubMed
42943387Precision Microbiome Interventions in Oncology: From Predictive Biomarkers to Therapeutic Modulation of Immunotherapy Outcomes.Microorganisms2026https://conductscience.org/library/papers/42943387PubMed
42941537Prediction of Pathological Complete Response to Neoadjuvant Immunotherapy-Based Regimens for Non-Metastatic Colon and Rectal Cancer.J Clin Med2026https://conductscience.org/library/papers/42941537PubMed
42941329Molecular Profiles, Treatment-Associated Survival, and Prognosis in Early-Onset Versus Late-Onset Gastric Cancer: A Systematic Review and Meta-Analysis.J Clin Med2026https://conductscience.org/library/papers/42941329PubMed
42936277WRN helicase addiction in MSI-H colorectal cancer: biomarker-guided pharmacology, resistance evolution, and implications for other gastrointestinal cancers.Front Pharmacol2026https://conductscience.org/library/papers/42936277PubMed
42928874Nanotechnology-Enabled Immunotherapy for Colorectal Cancer: Overcoming the "Cold" Tumor Microenvironment in Microsatellite-Stable Disease.Int J Nanomedicine2026https://conductscience.org/library/papers/42928874PubMed
42923368Induced mismatch repair deficiency: a hypothesis for the transient and reversible sensitization of mismatch repair-proficient tumors to Immune checkpoint blockade.Front Immunol2026https://conductscience.org/library/papers/42923368PubMed
42920873Unexpected favorable response of stage IV gastric adenocarcinoma to sintilimab combined with chemotherapy: A case report.Oncol Lett2026https://conductscience.org/library/papers/42920873PubMed
42910256Metabolic Barriers to Cancer Immunotherapy: Multiscale Mechanisms from Organelle Dysfunction to Organ-Specific Constraints.Int J Biol Sci2026https://conductscience.org/library/papers/42910256PubMed
42901717PCSK9 drives acquired resistance to anti-PD-1 immunotherapy through cystine metabolic reprogramming in lung cancer.J Immunother Cancer2026https://conductscience.org/library/papers/42901717PubMed
42897348Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.Nat Med2026https://conductscience.org/library/papers/42897348PubMed
42892624Single-cell RNA sequencing identifies a proinflammatory S100a8/a9+ macrophage subset contributing to acute kidney injury.Inflamm Res2026https://conductscience.org/library/papers/42892624PubMed
42882903Intensive Care in Patients with Solid Tumours: A Practical Framework for Integrated Onco-Critical Care.Cancers (Basel)2026https://conductscience.org/library/papers/42882903PubMed
42879043Resistance Phenotypes and Treatment Sequencing After Immune Checkpoint Blockade in MSI-H/dMMR Metastatic Colorectal Cancer: A Review.J Gastrointest Cancer2026https://conductscience.org/library/papers/42879043PubMed
42870820Exploratory study to evaluate the combined effect of CBM588: Clostridium butyricum in platinum plus pemetrexed with pembrolizumab for non-small cell lung cancer-protocol of MIYABRO study.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42870820PubMed

See all 4,039 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs6

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CAPECITABINECHEMBL1773Results1https://conductscience.org/library/drugs/CHEMBL1773ChEMBL
TUCIDINOSTATCHEMBL3621988Results1https://conductscience.org/library/drugs/CHEMBL3621988ChEMBL
CAMRELIZUMABCHEMBL4297715Results1https://conductscience.org/library/drugs/CHEMBL4297715ChEMBL
TISLELIZUMABCHEMBL4297840Results1https://conductscience.org/library/drugs/CHEMBL4297840ChEMBL
FRUQUINTINIBCHEMBL4303214Results1https://conductscience.org/library/drugs/CHEMBL4303214ChEMBL
GEMCITABINECHEMBL888Results1https://conductscience.org/library/drugs/CHEMBL888ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28596308

GET https://conductscience.org/api/papers/v1/28596308/authors?page=2